


## TP-030-2

<b>Cat. No.:</b>	HY-148239
<b>CAS No.:</b>	2095514-84-2
<b>Molecular Formula:</b>	C <sub>23</sub> H <sub>21</sub> BrN <sub>4</sub> O <sub>3</sub>
<b>Molecular Weight:</b>	481.34
<b>Target:</b>	RIP kinase; Ser/Thr Protease
<b>Pathway:</b>	Apoptosis; Metabolic Enzyme/Protease
<b>Storage:</b>	4°C, protect from light, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (207.75 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	2.0775 mL	10.3877 mL	20.7753 mL
5 mM	0.4155 mL	2.0775 mL	4.1551 mL
10 mM	0.2078 mL	1.0388 mL	2.0775 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

TP-030-2 is a RIPK1 inhibitor (human K<sub>i</sub>=0.43 nM; mouse IC<sub>50</sub>=100 nM)<sup>[1][2]</sup>.

#### In Vitro

TP-030-2 shows inhibition in HT29 with IC<sub>50</sub>=1.3 nM<sup>[2]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Yoshikawa M, et al. Discovery of 7-Oxo-2,4,5,7-tetrahydro-6 H-pyrazolo[3,4- c]pyridine Derivatives as Potent, Orally Available, and Brain-Penetrating Receptor Interacting Protein 1 (RIP1) Kinase Inhibitors: Analysis of Structure-Kinetic Relationships. J Med Chem. 2018 Mar 22;61(6):2384-2409.

[2]. <https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/TP-030-2>

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA